CONTEXT: Autoimmunity associated with Addison's disease (AD) can be detected by measuring 21-hydroxylase (21OH) autoantibodies. Subjects with type 1 diabetes (T1D) are at increased risk for AD. Genetic factors including HLA-DRB1*0404 and MICA have been associated with AD in populations with and without T1D. OBJECTIVE: The objective of the study was to examine the effect of the MICA5.1 allele in subjects with 21OH autoantibodies on progression to AD. DESIGN: Two components were used: 1) a cross-sectional study with subjects with AD identified and enrolled from September 1993 to November 2008 and 2) a cohort study prospectively following up patients with T1D who screened positive for 21OH autoantibodies. SETTING: Subjects were identified from the Barbara Davis Center and through the National Adrenal Diseases Foundation. PATIENTS: Sixty-three subjects with AD were referred through the National Adrenal Diseases Foundation (AD referrals). Sixty-three subjects with positive 21OH antibodies from the Barbara Davis Center were followed up for progression to AD, and 11 were diagnosed with AD (progressors). RESULTS: Seventy-three percent of progressors (eight of 11) and 57% of AD referrals (36 of 63) were MICA5.1 homozygous (P = ns). Overall, 59% of patients with AD (44 of 74) were MICA5.1/5.1 compared with 17% of nonprogressors (nine of 52) (P < 0.0001) and 19% of normal DR3/4-DQB1*0302 controls (64 of 336) (P < 0.0001). CONCLUSIONS: Identifying extreme risk should facilitate monitoring of progression from 21OH antibody positivity to overt AD. The HLA-DR3/0404 genotype defines high-risk subjects for adrenal autoimmunity. MICA5.1/5.1 may define those at highest risk for progression to overt AD, a feature unique to AD and distinct from T1D.
CONTEXT: Autoimmunity associated with Addison's disease (AD) can be detected by measuring 21-hydroxylase (21OH) autoantibodies. Subjects with type 1 diabetes (T1D) are at increased risk for AD. Genetic factors including HLA-DRB1*0404 and MICA have been associated with AD in populations with and without T1D. OBJECTIVE: The objective of the study was to examine the effect of the MICA5.1 allele in subjects with 21OH autoantibodies on progression to AD. DESIGN: Two components were used: 1) a cross-sectional study with subjects with AD identified and enrolled from September 1993 to November 2008 and 2) a cohort study prospectively following up patients with T1D who screened positive for 21OH autoantibodies. SETTING: Subjects were identified from the Barbara Davis Center and through the National Adrenal Diseases Foundation. PATIENTS: Sixty-three subjects with AD were referred through the National Adrenal Diseases Foundation (AD referrals). Sixty-three subjects with positive 21OH antibodies from the Barbara Davis Center were followed up for progression to AD, and 11 were diagnosed with AD (progressors). RESULTS: Seventy-three percent of progressors (eight of 11) and 57% of AD referrals (36 of 63) were MICA5.1 homozygous (P = ns). Overall, 59% of patients with AD (44 of 74) were MICA5.1/5.1 compared with 17% of nonprogressors (nine of 52) (P < 0.0001) and 19% of normal DR3/4-DQB1*0302 controls (64 of 336) (P < 0.0001). CONCLUSIONS: Identifying extreme risk should facilitate monitoring of progression from 21OH antibody positivity to overt AD. The HLA-DR3/0404 genotype defines high-risk subjects for adrenal autoimmunity. MICA5.1/5.1 may define those at highest risk for progression to overt AD, a feature unique to AD and distinct from T1D.
Authors: J G Bodmer; S G Marsh; E D Albert; W F Bodmer; B Dupont; H A Erlich; B Mach; W R Mayr; P Parham; T Sasazuki Journal: Eur J Immunogenet Date: 1992-10
Authors: M Ota; Y Katsuyama; N Mizuki; H Ando; K Furihata; S Ono; P Pivetti-Pezzi; K F Tabbara; G D Palimeris; B Nikbin; F Davatchi; H Chams; Z Geng; S Bahram; H Inoko Journal: Tissue Antigens Date: 1997-05
Authors: M Rewers; T L Bugawan; J M Norris; A Blair; B Beaty; M Hoffman; R S McDuffie; R F Hamman; G Klingensmith; G S Eisenbarth; H A Erlich Journal: Diabetologia Date: 1996-07 Impact factor: 10.122
Authors: A Falorni; A Nikoshkov; S Laureti; E Grenbäck; A L Hulting; G Casucci; F Santeusanio; P Brunetti; H Luthman; A Lernmark Journal: J Clin Endocrinol Metab Date: 1995-09 Impact factor: 5.958
Authors: S Laureti; A De Bellis; V I Muccitelli; F Calcinaro; A Bizzarro; R Rossi; A Bellastella; F Santeusanio; A Falorni Journal: J Clin Endocrinol Metab Date: 1998-10 Impact factor: 5.958
Authors: Peter R Baker; Priyaanka Nanduri; Peter A Gottlieb; Liping Yu; Georgeanna J Klingensmith; George S Eisenbarth; Jennifer M Barker Journal: Clin Endocrinol (Oxf) Date: 2012-05 Impact factor: 3.478
Authors: Peter R Baker; Erin E Baschal; Pam R Fain; Priyaanka Nanduri; Taylor M Triolo; Janet C Siebert; Taylor K Armstrong; Sunanda R Babu; Marian J Rewers; Peter A Gottlieb; Jennifer M Barker; George S Eisenbarth Journal: J Clin Endocrinol Metab Date: 2011-05-11 Impact factor: 5.958
Authors: Peter R Baker; Erin E Baschal; Pam R Fain; Taylor M Triolo; Priyaanka Nanduri; Janet C Siebert; Taylor K Armstrong; Sunanda R Babu; Marian J Rewers; Peter A Gottlieb; Jennifer M Barker; George S Eisenbarth Journal: J Clin Endocrinol Metab Date: 2010-07-14 Impact factor: 5.958